# Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer

> **NCT02964559** · PHASE2 · COMPLETED · sponsor: **Emory University** · enrollment: 11 (actual)

## Conditions studied

- Recurrent Skin Carcinoma
- Skin Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02964559
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-27
- **Primary completion:** 2021-05-18
- **Final completion:** 2021-05-18
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2024-06-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02964559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02964559, "Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02964559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*